Ceftolozane Sulfate

China [CN]

Core Uses

Approved Indications (all administered intravenously, in combination with tazobactam):

Complicated urinary tract infections (cUTI) (including pyelonephritis, adults)

Complicated intra-abdominal infections (cIAI) (adults, in combination with metronidazole)

Hospital-acquired pneumonia (HAP) / Ventilator-associated pneumonia (VAP) (adults)

Acute bacterial skin and soft tissue infections (ABSSSI) (adults)

Mechanism: Binds to PBPs to inhibit cell wall synthesis; synergizes with tazobactam to protect ceftolozane from degradation by β-lactamases; unique outer membrane penetration, overcoming the permeability barrier of MDR-PA, achieving anti-MDR-PA activity.

2. Key Clinical Information

Dosage Form: Sterile powder for injection (combination: ceftolozane 1g + tazobactam 0.5g / vial)

Dosage and Administration: Adults 1g/0.5g every 8 hours, intravenous infusion over 1 hour; dose reduction required for patients with renal impairment (CrCl < 50 mL/min)

Core Advantages:

Anti-MDR-PA: Superior activity against carbapenem-resistant Pseudomonas aeruginosa compared to ceftazidime/avibactam and meropenem

Highly Enzyme Stable: Stable against serine β-lactamases such as ESBL, AmpC, and KPC (partially)

Combination Synergy: Tazobactam enhances activity against enzyme-producing strains, expanding coverage

Suitable for Severe Cases: Used for hospital-acquired multidrug-resistant bacterial infections, filling a clinical gap